STING1 and neoplasm: Recently, PARP inhibitors have been shown to activate anti-tumor immune responses via the STING (stimulator of interferon genes) pathway, potentially sensitizing tumors to ICB and expanding their role in the treatment of gynecologic malignancies [19].